Abstract
Background: Diabetic retinopathy (DR) development
is associated with disturbances in the gut microbiota and related metabolites.
Butyric acid is one of the short-chain fatty acids (SCFAs), which has been
found to possess a potential antidiabetic effect. However, whether butyrate has
a role in DR remains elusive. This study aimed to investigate the effect and
mechanism of sodium butyrate supplementation on DR.
Methods: C57BL/6J mice were divided into three
groups: Control group, diabetic group, and diabetic with butyrate
supplementation group. Type 1 diabetic mouse model was induced by
streptozotocin. Sodium butyrate was administered by gavage to the experimental
group daily for 12 weeks. Optic coherence tomography, hematoxylin-eosin, and
immunostaining of whole-mount retina were used to value the changes in retinal
structure. Electroretinography was performed to assess the retinal visual
function. The tight junction proteins in intestinal tissue were evaluated using
immunohistochemistry. 16S rRNA sequencing and LC-MS/MS were performed to
determine the alteration and correlation of the gut microbiota and systemic
SCFAs.
Results: Butyrate decreased blood glucose, food, and
water consumption. Meanwhile, it alleviated retinal thinning and activated
microglial cells but improved electroretinography visual function.
Additionally, butyrate effectively enhanced the expression of ZO-1 and Occludin
proteins in the small intestine. Crucially, only butyric acid, 4-methylvaleric
acid, and caproic acid were significantly decreased in the plasma of diabetic
mice and improved after butyrate supplementation. The deeper correlation
analysis revealed nine genera strongly positively or negatively correlated with
the above three SCFAs. Of note, all three positively correlated genera,
including norank_f_Muribaculaceae, Ileibacterium, and Dubosiella, were
significantly decreased in the diabetic mice with or without butyrate
treatment. Interestingly, among the six negatively correlated genera,
Escherichia-Shigella and Enterococcus were increased, while Lactobacillus,
Bifidobacterium, Lachnospiraceae_NK4A136_group, and
unclassified_f_Lachnospiraceae were decreased after butyrate supplementation.
Conclusion: Together, these findings demonstrate the
microbiota regulating and diabetic therapeutic effects of butyrate, which can
be used as a potential food supplement alternative to DR medicine.
Keywords: 4-Methylvaleric acid; Caproic acid; Diabetic
retinopathy; Gut microbiota; Short-chain fatty acids; Sodium butyrate.